Literature DB >> 12531411

Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome.

Kim C Lu1, Andrés Jaramillo, Eric N Mendeloff, Charles B Huddleston, Stuart C Sweet, G Alexander Patterson, T Mohanakumar.   

Abstract

BACKGROUND: The authors' previous studies with 2 different adult patient populations demonstrated a correlation between indirect allorecognition of mismatched donor HLA Class I- and Class II-derived peptides and the development of bronchiolitis obliterans syndrome (BOS) after lung transplantation. The aim of this study was to determine whether a parallel allorecognition of mismatched donor HLA Class I- and Class II-derived peptides occurs after lung transplantation and to determine its correlation with the development of BOS after lung transplantation in a group of pediatric patients.
METHODS: Peripheral blood mononuclear cells from 7 BOS-positive and 6 BOS-negative pediatric lung transplant recipients (age, 11.5 +/- 4.4 years) were cultured in the presence of synthetic peptides corresponding to the alpha-chain hypervariable regions of a mismatched donor HLA Class I molecule and the beta-chain hypervariable region of a mismatched donor HLA-DR molecule. The frequencies of HLA Class I and Class II alloreactive T cells were determined using limiting dilution analysis.
RESULTS: A significant increase (p = 0.025) in HLA Class I-alloreactive T cells was observed in BOS-positive patients (7.1 x 10(-5) +/- 4.3 x 10(-5)) compared with BOS-negative patients (2.1 x 10(-5) +/- 1.8 x 10(-6)). In addition, a significant increase (p = 0.033) in HLA Class II-alloreactive T cells also was observed in BOS-positive patients (9.6 x 10(-5) +/- 7.9 x 10(-5)) compared with BOS-negative patients (1.3 x 10(-5) +/- 2.1 x 10(-6)).
CONCLUSIONS: This study indicates that a parallel CD4+ T-cell alloreactivity to both donor HLA Class I and Class II molecules may play a role in the pathogenesis of BOS both in adult and pediatric lung transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531411     DOI: 10.1016/s1053-2498(02)00478-3

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  9 in total

Review 1.  Allopeptides and the alloimmune response.

Authors:  Ankit Bharat; T Mohanakumar
Journal:  Cell Immunol       Date:  2007-07       Impact factor: 4.868

Review 2.  Regulatory T cell-mediated transplantation tolerance.

Authors:  Ankit Bharat; Ryan Courtney Fields; T Mohanakumar
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts.

Authors:  Deepti Saini; Joseph Weber; Sabarinathan Ramachandran; Donna Phelan; Venkataswarup Tiriveedhi; Michael Liu; Nancy Steward; Aviva Aloush; Ramsey Hachem; Elbert Trulock; Bryan Meyers; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2011-03-16       Impact factor: 10.247

4.  Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations.

Authors:  Venkataswarup Tiriveedhi; Baskaran Gautam; Nayan J Sarma; Medhat Askar; Marie Budev; Aviva Aloush; Ramsey Hachem; Elbert Trulock; Bryan Myers; Alexander G Patterson; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2013-08       Impact factor: 10.247

5.  Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation.

Authors:  Deepti Saini; Nataraju Angaswamy; Venkataswarup Tiriveedhi; Naohiko Fukami; Sabarinathan Ramachandran; Ramsey Hachem; Elbert Trulock; Brian Meyers; Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2010-08-05       Impact factor: 10.247

6.  Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies.

Authors:  Haseeb Ilias Basha; Sabarinathan Ramachandran; Venkataswarup Tiriveedhi; Masashi Takenaka; Vijay Subramanian; Dilip S Nath; Nicholas Benshoff; G Alec Patterson; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

7.  The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.

Authors:  Xiaoqin Hua; Tobias Deuse; Yi-Je Chen; Heike Wulff; Mandy Stubbendorff; Ralf Köhler; Hiroto Miura; Florian Länger; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

8.  Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation.

Authors:  Anjali S Golocheikine; Deepti Saini; Sabarinathan Ramachandran; Elbert P Trulock; Alexander Patterson; T Mohanakumar
Journal:  Transpl Immunol       Date:  2007-09-11       Impact factor: 1.708

9.  Antibodies to MHC class II molecules induce autoimmunity: critical role for macrophages in the immunopathogenesis of obliterative airway disease.

Authors:  Masashi Takenaka; Venkataswarup Tiriveedhi; Vijay Subramanian; Kiyotaka Hoshinaga; Alexander G Patterson; Thalachallour Mohanakumar
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.